Archive January 24, 2022 Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
Archive January 10, 2022 Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones
Archive January 3, 2022 Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
Archive December 21, 2021 Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Archive November 30, 2021 Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations
Archive November 22, 2021 Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Archive November 5, 2021 Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study
Archive November 2, 2021 Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results
Archive October 26, 2021 Deciphera Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 2, 2021
Archive October 12, 2021 Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
